Author: Ravi Shankar

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with SOQUEM Inc. (“SOQUEM”), is pleased to announce the results of the 2026 exploration campaign on the Nachicapau project (Figure 1). This exploration program follows the discovery, between 2022 and 2025, of copper, gold and silver occurrences along a 4-km-long by 1.5-km-wide corridor. These new results are reported under the Strategic Alliance between Midland and SOQUEM (the “Alliance”) in the Labrador Trough in Nunavik, Quebec.

Highlights:

• Discovery of copper, gold and silver mineralization with maximum values reaching 26.8% Cu, 0.87 g/t Au, 238 g/t Ag (grab samples from boulders) associated with digenite and malachite in veins hosted in monzonite dykes.
• Two new copper, gold and silver showings on outcrops with maximum values reaching 3.03% Cu, 0.77 g/t Au, 20.0 g/t Ag (from different grab samples).
• Identification of induced polarization (“IP”) anomalies associated with Cu, Au, Ag mineral occurrences.

The 2026 sampling campaign was conducted over a period of 5 days in June, during which a total of 54 rock samples were collected. The campaign was designed to follow up on chargeability and conductivity anomalies outlined by the Orevision® induced polarization survey conducted in 2025 (figures 2 and 3).

Assay results reveal that ten (10) grab samples show grades equal to or greater than 0.10% Cu, including four (4) samples above 1.00% Cu, reaching up to 26.8% Cu. Anomalous gold values above 0.1 g/t Au are associated with these samples, while three (3) samples exhibit silver values reaching up to 238 g/t Ag. These results highlight a close relationship between Cu, Au, Ag mineralization and the presence of monzonite dykes, alkalic ultramafic units, and regional structural features. Best results obtained in grab samples are listed in Table 1.

Table 1: Best Cu, Au, Ag Assay Results from 2026 Grab Samples.

Sample Number	NAD 83 Zone 19 (m)		Type	Host Rock	Cu	Au	Ag
	UTM E	UTM N			(%)	(g/t)	(g/t)
C2130702	558492	6277160	Boulder	Monzonite dyke	26.8	0.24	238
C2130681	559665	6275540	Boulder	Monzonite dyke	14.8	0.65	112
C2130703	558467	6277165	Boulder	Monzonite dyke	7.68	0.87	57.2
C2130684	559755	6275419	Outcrop	Monzonite dyke	3.03	0.17	20.0
C2130669	559048	6276572	Outcrop	Monzonite dyke	0.59	0.77	10.3
C2130682	559665	6275540	Boulder	Monzonite dyke	0.35	0.04	2.15
C2130704	558460	6277184	Boulder	Ultramafic schist	0.28	0.07	1.53
C2130685	559643	6275552	Outcrop	Monzonite dyke	0.10	0.01	1.37
C2130668	559054	6276556	Outcrop	Monzonite dyke	0.10	0.02	1.33
C2130651	558596	6277088	Outcrop	Ultramafic schist	0.10	0.13	0.76

Digenite, Bornite and Malachite Mineralization Associated with Monzonite Dykes

The best results of the June 2026 campaign were obtained in grab samples collected in boulders, consisting of calcite-dolomite-quartz veins crosscutting a monzonite. The mineralization is characterized by the presence of centimetre-scale patches of digenite and malachite within the veins and in their selvages (Figure 4a to 4c). Hematite is a common accessory mineral and occurs as distinctive specularite crystals. The host rock is weakly deformed and systematically altered to albite, epidote and hematite.

On outcrop, these dykes crosscut, at low angles, alkalic mafic to ultramafic volcanic units of the Murdoch Formation (Figure 4d). Copper mineralization occurs in calcite-dolomite-quartz tension gashes. Sample C2130669, which graded 0.59% Cu, 0.77 g/t Au, 10.3 g/t Ag, confirms the extension of both the mineralized zone and the monzonite dyke north of the DG-12 showing discovered in 2025 (1.46% Cu, 0.14 g/t Au, 9.20 g/t Ag in a monzonite dyke).

Samples C2130681 to C2130685, collected on either side of the DG-5 showing (2.95% Cu, 0.01 g/t Au, 27.6 g/t Ag) confirm observations and interpretations made in 2025 and extend the mineralized zones associated with monzonite dykes over a distance of 150 metres. Sample C2130684, collected in a digenite-malachite vein, yielded showing-level grades of 3.03% Cu, 0.17 g/t Au and 20.0 g/t Ag.

Mineralization Associated with Mafic to Ultramafic Volcanic Units

Three (3) samples collected in ultramafic schist and intrusive units yielded anomalous Cu, Au and Ag values. Sample C2130651, which did not appear to be mineralized, yielded values of 0.10% Cu, 0.13 g/t Au, 0.76 g/t Ag, i.e. respectively 30 to 100 times higher than regional background values. This observation suggests that copper mineralization is not exclusively found in veins but may also occur disseminated within deformed and altered ultramafic units.

2025 OreVision® Induced Polarization Survey

Follow-up work on the OreVision® induced polarization survey conducted in July 2025 helped improve our understanding of the geological setting and Cu-Au-Ag mineral occurrences on the Nachicapau project. Sedimentary units (dolomite, mudstone), mafic intrusives, and ultramafic schists can be distinguished based on resistivity and chargeability contrasts. Copper mineralization is closely linked with low-resistivity (<6,000 Ohm.m) and moderate chargeability (7–14 mV/V) zones within the ultramafic schist unit and along the contact with sedimentary units (Figure 5).

Conclusions

Cu-Au-Ag mineralization on the Nachicapau project appears to be related to:

• Deformed and altered mafic to ultramafic volcanic units of the Murdoch Formation, where it occurs as disseminated digenite and malachite
• Monzonite dykes where it occurs in veins with higher-grade Cu, Au, Ag
• Intense albite-epidote-hematite alteration occurring around the veins
• Low-resistivity copper mineralization (<6,000 Ohm.m) and moderate-chargeability
  (7–14 mV/V) zones
• A deformation corridor trending N350 that affects volcanic units
• A major shear zone that marks the contact with sedimentary units

Quality Control

Rock samples from the project are analyzed at Actlabs laboratories in Ancaster, Ontario, by ICP-MS with four-acid digestion for metals and by standard fire assay on 50-gram fractions with atomic absorption finish for gold. Exploration programs are designed, and results are interpreted by Qualified Persons employing a Quality Assurance/Quality Control program consistent with industry best practices, including the use of standards and blanks for every 20 samples.

Cautionary Statements

Grab samples are selective by nature and may not be representative of mineralized zones. Mineralization observed in samples collected from boulders, outcrops and showings mentioned in this press release is not necessarily indicative of mineralization that may be found on the project mentioned in this press release.

About the Strategic Alliance with SOQUEM

The Strategic Alliance enables Midland and SOQUEM to combine their efforts and expertise to jointly explore the excellent potential for gold and strategic minerals of the vast and underexplored Labrador Trough. The area of interest defined under the Alliance is located in Nunavik. Geologically, it covers the Labrador Trough, the Rachel-Laporte Zone, and the Kuujjuaq Domain. The area of interest extends from Schefferville in the south up to approximately 100 km northwest of Kangirsuk. Executed in November 2021, the initial agreement called for investments in exploration reaching up to $4 million over a period of four (4) years, in addition to investments on the Nachicapau project.

In 2026, the parties confirmed the continuation of the Alliance with a joint annual exploration budget of $1 million (50% Midland and 50% SOQUEM) on the Malaco Mountain and Nachicapau projects.

About SOQUEM

SOQUEM is a mineral exploration company and a subsidiary of Investissement Québec. Its mission is to explore, discover, and develop Quebec’s mineral resources. SOQUEM also contributes to maintaining a strong economy in Quebec’s regions. A proud partner and ambassador for the development of Quebec’s mineral wealth, SOQUEM relies on innovation, research and strategic minerals to be well positioned for the future.

About Midland

Midland targets the mineral potential of Quebec to make the discovery of new deposits of gold and critical metals. Midland is proud to count on reputable partners such as SOQUEM Inc., Rio Tinto Exploration Canada Inc., BHP Canada Inc., Centerra Gold Inc., Barrick Gold Corporation, Agnico Eagle Mines Limited, Wallbridge Mining Company Ltd., Fresnillo plc, Electric Elements Mining Corp., Nunavik Mineral Exploration Fund and Abcourt Mines Inc. Midland prefers to work in partnership and intends to quickly conclude additional agreements in regard to newly acquired properties. Management is currently reviewing other opportunities and projects to build up the Company portfolio and generate shareholder value.

Qualified Person and Exploration Director Richard D. St-Cyr, P.Geo., reviewed and approved this press release and the Nachicapau project data as Midland’s Qualified Person (QP) within the meaning of National Instrument 43–101.

For further information, please consult Midland’s website or contact:

Gino Roger, President and Chief Executive Officer
Tel.: 450 420-5977
Fax: 450 420-5978
Email: info@midlandexploration.com
Website: https://www.midlandexploration.com/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include statements relating to management expectations regarding the conclusion of additional agreements in regard to newly acquired properties, and other estimates and statements that describe Midland’s future plans, objectives or goals, including words to the effect that Midland or management expects a stated condition or result to occur. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, changes in general economic conditions and conditions in the financial markets, changes in demand and prices for minerals, failure to obtain the requisite permits and approvals from government bodies and third parties, regulatory and governmental policy changes (laws and policies) and those risks set out in Midland’s public documents, including in each management discussion and analysis, filed on SEDAR+ at www.sedarplus.com. Although Midland believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Midland disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cd46a469-0e89-47b9-b764-b5c3d88292ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d0d4-b053-4362-ab42-1914a717bd6b
https://www.globenewswire.com/NewsRoom/AttachmentNg/f348bf20-b379-467c-adb4-4697ee130727
https://www.globenewswire.com/NewsRoom/AttachmentNg/d45930ab-89a9-4a3a-a6ee-3e76a351543a
https://www.globenewswire.com/NewsRoom/AttachmentNg/aca54b4f-ff84-4f5e-ab73-aeabc030038c

Calgary, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV:SEGN) (“Seegnal” or the “Company”), today announced that its investor relations technologies and services agreement dated March 26, 2026 (“Services Agreement”) with CapitaLynx Ltd. will conclude effective September 26, 2026.

The Services Agreement was previously disclosed in the Company’s news release dated April 1, 2026. During the engagement, the Company rebuilt its investor materials, narrative positioning and investor portal and upgraded its core investor relations assets. The Company intends to continue to use those materials, infrastructure and technologies. The Company wishes to thank CapitaLynx for its services and contributions during the engagement.

About Seegnal
Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company’s SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal’s technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice. For additional Company information, please visit https://investors.seegnal.com/ and follow us on LinkedIn.

Seegnal Media Contact:
Elad Bibi-Aviv
Chief Executive Officer press@seegnal.com
+972-52-533-0856
www.seegnal.com

Forward-Looking Information
This press release contains “forward-looking information” or “forward-looking statements” within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the “About Seegnal” section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate”, “believes”, “estimates”, “expects”, “intends”, “may”, “should”, “will” or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements with respect to the conclusion of the Services Agreement and the Company’s intention to continue using materials, infrastructure and technologies developed during the engagement. Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORT WORTH, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management and healthcare solutions, today announced the availability of its Care^MC Accelerator for Guidewire ClaimCenter, enabling Managed Care services to be initiated and managed directly within the claims workflow.

Designed for Guidewire Cloud and aligned with Guidewire standards, the Care^MC Accelerator connects claims activity with Managed Care operations through secure Single Sign‑On (SSO) and structured data exchange. This integration delivers a streamlined experience where key actions and information are available at the point of decision, reducing friction and improving workflow efficiency.

Streamlined Access and Data Exchange

The Care^MC Accelerator, now available on Guidewire Marketplace, enables carriers to connect claims and Managed Care processes through:

• Direct access to CorVel Managed Care services from within ClaimCenter
• Secure SSO to support streamlined navigation across systems
• Automated transfer of claim and injury data to initiate services
• Real‑time return of Managed Care status updates, recommendations, and outcomes

By coordinating how information moves across systems, teams gain clearer insight into case activity and can take action without unnecessary disruption.

Practical Benefits for Claims and Managed Care Teams

With this integration, users can:

• Initiate and coordinate care services within their existing claims environment
• Eliminate duplicate data entry and reduce administrative steps
• Track Managed Care activity in real time
• Make faster, more informed decisions with guided visibility into care activity

Scalable Integration Built for Adoption

CorVel’s Accelerator supports flexible implementation and long‑term scalability. By leveraging Guidewire integration standards, the Care^MC Accelerator reduces technical complexity while allowing carriers to configure workflows that align with their operating models.

Key advantages include:

• Faster and more predictable implementation timelines
• Reduced demand on IT resources
• Configurable workflows and business rules
• Simplified evaluation and deployment through the Guidewire Marketplace

Supporting Modern Claims Operations

This integration enables managed care to function as a coordinated part of the claims process rather than a separate downstream activity. Teams benefit from improved continuity and greater confidence that medical aspects of a claim are being addressed alongside claims handling.

“Moving to CorVel has never been easier, not because claims environments are simple, but because our integrations are designed to align with how carriers operate,” said Ron Wojciechowski, Senior Vice President of Payer Technical Solutions at CorVel. “Our Care^MC Accelerator supports efficient adoption while helping teams stay focused on outcomes.”

Additional details are available through Guidewire Marketplace.

About CorVel
CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, improved productivity resulting from automation and augmentation across enterprise business systems. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com

Award Strengthens Regional Supply Chain and Advances Edible Garden’s Zero-Waste Inspired® Mission and Farm-to-Formula® Platform

BELVIDERE, NJ, Sept. 22, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded fresh-cut herb business through an additional Walmart distribution center serving the Upper Midwest. The award builds upon the Company’s recently announced expansion with Walmart in the Mid-Atlantic region and extends Edible Garden’s growing retail presence into the Upper Midwest.

The additional distribution center will be serviced by Edible Garden Heartland in Grand Rapids, Michigan, further diversifying the facility’s customer base while supporting the Company’s strategy of creating a more centralized, scalable and efficient distribution network. The Company believes the award has the potential to increase fresh-cut herb volume and improve operating efficiencies as demand grows, while providing a foundation for Edible Garden to pursue additional stores, products and regional opportunities with Walmart and other major retailers.

“This award represents another important expansion of our relationship with Walmart and establishes an additional supply-chain position for Edible Garden in the Upper Midwest,” said Jim Kras, Chief Executive Officer of Edible Garden. “We believe it reflects Walmart’s confidence in our ability to consistently deliver fresh, high-quality herbs while meeting the food-safety, reliability, and service requirements of one of the world’s largest retailers. Just as importantly, the award advances our transition toward a more efficient distribution-center model. By consolidating shipments through Walmart’s distribution network, we believe we can improve route density, reduce fragmented deliveries and scale more efficiently as demand grows, while reducing unnecessary transportation, handling, and potential food waste. This approach supports our Zero-Waste Inspired® mission while building a stronger and more resilient distribution platform that can support our fresh herb business today and provide a commercial foundation for future Farm-to-Formula® products and other opportunities across our broader food and nutrition portfolio.”

Edible Garden’s distribution strategy is supported by its proprietary GreenThumb 2.0™ technology, which helps the Company synchronize growing, inventory, and retailer demand. By improving visibility across its supply chain, the Company seeks to enhance forecasting and fulfillment, preserve product freshness and reduce excess inventory and waste.

Edible Garden’s work with Walmart also reflects the Company’s broader commitment to sustainable operations. The Company is a multi-year participant in Walmart’s Project Gigaton and has been recognized as a Giga Guru for its efforts to measure, manage and reduce emissions across its operations and supply chain.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000^th Tibia Nail using its latest Pediatric Nailing Platform (PNP).

The PNP Tibia System was designed to bring a world-class, pediatric-focused nailing system to surgeons, enabling the use of rigid tibial nails in pediatric patients.

OrthoPediatrics’ introduction of the 7mm cannulated rigid tibial nail, the only product of its size, enables surgeons to treat patients who have previously been untreatable with adult systems. In fact, nearly 20% of all nails implanted by OrthoPediatrics have been the smallest 7mm size available. The implant is available in 7mm-12mm diameters.

Joe Hauser, President of Trauma & Deformity, stated, “The rapid adoption of this system demonstrates that OrthoPediatrics is filling a critical void in implant offerings to our core customer. The surgeon design team and our OrthoPediatrics engineers were meticulous in developing a system purpose-built for the needs of pediatric patients, and it is proving to be a valuable tool in treating over 1,000 kids with tibia fractures.”

The system includes small instruments to access the intramedullary canal, smaller overall nails, fixation options designed to avoid the physis, and instrumentation supporting both traditional and suprapatellar approaches.

PNP Tibia is currently available in five markets, with a European launch planned for 2027.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) will be presented at two upcoming scientific meetings: the 6^th International Symposium on IgG4-Related Disease, taking place October 8-10, in Cambridge, Massachusetts, and American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11, 2026, in Orlando, Florida.

Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6^th International Symposium on IgG4-Related Disease. Additional presentations across both meetings include analyses evaluating glucocorticoid-associated toxicity and vaccine responses among patients with IgG4-RD treated with obexelimab.

“Zenas is committed to advancing the scientific understanding of IgG4-RD and the potential role of obexelimab in addressing the needs of people living with this rare, chronic, immune-mediated disease,” said Lisa von Moltke, MD, Head of Research and Development and Chief Medical Officer of Zenas. “The upcoming presentations at the IgG4ward! 6^th International Symposium on IgG4-RD and ACR Convergence 2026 build on the Phase 3 INDIGO results presented earlier this year and reflect our continued focus on advancing therapies that may help people living with IgG4-RD.”

Presentation Details

Details of 6^th International Symposium on IgG4-Related Disease Presentations:

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Poster Viewing Session
Session Date & Time: Thursday, October 8; 5:00-7:00pm ET
Location: Charles Hotel-Boston

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results From the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:00am ET
Location: Charles Hotel-Boston

Title: Longer-Term Efficacy and Safety of Obexelimab in IgG4-Related Disease: Results from the Phase 3 INDIGO Open-Label Extension
Presenting Author: Emma Culver, Dphil, MBChB – University of Oxford
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:40am ET
Location: Charles Hotel-Boston

Details of ACR Convergence 2026 Presentations:

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results from the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Miscellaneous Rheumatic & Inflammatory Diseases I
Session Date & Time: Monday, November 9; 1:30pm-1:45pm ET
Abstract Number: 1882
Location: Oral presentation, W304 A-H

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Miscellaneous Rheumatic & Inflammatory Diseases; Poster Session C
Session Date & Time: November 10; 10:30am-12:30pm ET
Abstract Number: 2612
Location: Poster Hall

About Obexelimab
Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively modulate the pathogenic role of the B cell lineage in chronic autoimmune disease.

Obexelimab has been evaluated in nine clinical trials in a total of 667 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.

About IgG4-RD
IgG4-related disease (IgG4-RD) is a rare, chronic immune-mediated disease that can cause inflammation and fibrosis in multiple organs throughout the body. Because symptoms can appear suddenly or develop gradually—and may be mistaken for other conditions—many people face a 5–7-year journey to diagnosis. IgG4-RD can worsen and cause irreversible damage if it is not diagnosed and managed properly. About 20,000 people in the United States have been diagnosed with IgG4-RD, but the true number of people living with the disease may be closer to 40,000 because some individuals remain undiagnosed.

About Zenas BioPharma
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward looking statements include, but are not limited to, the anticipated timing or likelihood of regulatory submissions and approvals, and the outcome of interactions with regulatory authorities; the therapeutic potential of the Company’s product candidates; the Company’s expectations regarding the potential commercialization, estimated market size and market opportunities of its product candidates; and the timing of reporting the topline results of obexelimab in SLE. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results, performance or achievements to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements; the Company’s ability to obtain regulatory approval to commercialize its product candidates; risks related to the manufacturing of the Company’s product candidates and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the its license obligations; significant political, trade, and regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company’s suppliers, many of which are located outside of the United States, including the Company’s current sole contract manufacturing organization for obexelimab drug substance and drug product, WuXi Biologics (Hong Kong) Limited, and our partner, InnoCare, both of which are located in China; the risk that the Company’s indebtedness could adversely affect the Company’s financial condition or restrict the Company’s future operations; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented from time to time by our subsequent filings with the Securities and Exchange Commission (the “SEC”), as well as other information we file with the SEC. The forward-looking statements in this press release are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete. Because forward-looking statements are inherently subject to risks and uncertainties, these forward-looking statements should not be relied upon as guarantees of future events. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Ruihe Data Technology Holdings Limited (HKEX: 3680; OTCQX: RHDTY), an investment holding company, has qualified to trade on the OTCQX® Best Market. Ruihe Data Technology Holdings Limited upgraded to OTCQX from the Pink Limited™ Market.

Ruihe Data Technology Holdings Limited begins trading today on OTCQX under the symbol “RHDTY.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Ruihe Data Technology Holdings Limited is a leading enterprise in China’s data intelligence and marketing technology. It provides financial institutions, government agencies, and enterprises with solutions and consulting services in big data decision-making, artificial intelligence, digital marketing, and the domestic information technology innovation industry.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

“The Company regards the upgrade from the Pink Limited Market to the OTCQX Market as a significant milestone. It showcases the Company’s qualifications and raises its profile among U.S. investors. This upgrade is expected to broaden the Company’s investor base and enhance liquidity, aligning with the interests of the Company and its shareholders,” said Ruihe Data Technology Holdings Ltd. Chairman and CEO Shouguang Xue.

Trading in Asia Pacific securities on the OTC Markets reached U.S. $19.49B in the second quarter of 2026, representing a 34.1% increase over Q2 2025. OTC Markets recorded U.S. $453.34B in total dollar volume in the first half of the year. Asia Pacific markets ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Ruihe Data Technology Holdings Limited
The Company is a company incorporated in the Cayman Islands with limited liability and is an investment holding company. The Group is principally engaged in the provision of data solutions, integrated sales of hardware and software and related services, information technology maintenance and support services, commodity trading, cryptocurrency mining and investment in high-tech business

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

New results include 37.89 meters grading 5.29 g/t gold and 14.0 meters grading 13.09 g/t gold, as Dundee-funded technical programs advance the project toward a resource estimate and pre-feasibility study

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (“Dundee” or the “Corporation”) is pleased to report the sixth batch of assay results from ongoing resource infill drilling at Westhaven Gold Corp’s (“Westhaven”) South Zone gold and silver deposit on the Shovelnose gold property in southern British Columbia. The 35,000m infill program continues to be supported by four drills and is on track for completion by the end of September at which point the current 15,000m exploration drilling program will increase from one to four drills. Additionally, field activities have been expanded with initiation of a CDN$4,000,000 sonic drilling program intended to advance geotechnical and hydrogeology investigations in support of the South Zone pre-feasibility study (PFS), targeting completion in H2 2027.

Key Highlights:

• New South Zone infill drill results include highlight assays of:
  • 37.89m grading 5.29 g/t Au and 31.9 g/t Ag
  • 14.00m grading 13.09 g/t Au and 105.8 g/t Ag
  • 32.06m grading 5.05 g/t Au and 28.1 g/t Ag
  • 30.00m grading 2.34 g/t Au and 15.9 g/t Ag
  • 2.62m grading 13.81 g/t Au and 26.6 g/t Ag

• Resource infill drilling is on schedule for completion by the end of September and exploration drilling program to ramp up from one to four drills.
• CDN$4,000,000 geotechnical and hydrogeology drill program initiated.

“The consistency of these drill results continues to support our high conviction in the quality of the South Zone deposit.” said Jonathan Goodman, President and CEO of Dundee Corporation. “Importantly, the program is now transitioning from resource definition to exploration as well as the technical work required to support development of the mine. Dundee’s capital is intended to accelerate that progression, and we are encouraged by the pace at which the Westhaven Dundee Joint Venture is advancing the project toward an updated resource estimate and pre-feasibility study.”

On February 23, 2026, the Corporation completed a strategic earn-in agreement with Westhaven, whereby Dundee may earn up to a 60% interest in Westhaven’s four Spences Bridge Gold Belt properties through up to CDN$85,000,000 in staged project expenditures. Under the first phase, Dundee has committed a minimum of CDN$30,000,000, inclusive of a fully funded 50,000m drill program at Shovelnose, which is funding the activities outlined in this news release and is expected to continue through the remainder of 2026.

South Zone Mineral Resource Infill Drilling

Assay results from the ongoing 35,000m resource infill drilling program at the South Zone deposit continue to show excellent continuity of mineralization in each of Vein Zones 1, 2 and 3. All Assay Results related to the additional 13 infill drill holes are reported in Table 1, bringing the total number of reported drillholes to 72. For previously reported assay results from the South Zone mineral resource drilling program, please refer to the Corporation’s press releases dated May 7, 2026, May 26, 2026, July 7, 2026, July 28, 2026 and August 20, 2026. The resource drilling program has been designed to infill the deposit at nominal 25m centres with results to be included in an updated mineral resource estimate to support a PFS targeting completion in H2 2027. To date, 109 drill holes (34,265m) have been completed, with 6 holes remaining to completion of the program.

Selected assay highlights include:
SNR26-108:	37.89m grading 5.29 g/t Au & 32 g/t Ag from 183.11m downhole
SNR26-116:	32.06m grading 5.05 g/t Au & 28 g/t Ag from 223.00m downhole
SNR26-120:	30.00m grading 2.34 g/t Au & 16 g/t Ag from 210.50m downhole
SNR26-124:	7.45m grading 4.99 g/t Au & 81 g/t Ag from 215.85m downhole; and
	14.94m grading 2.61 g/t Au & 16 g/t Ag from 227.52m downhole
SNR26-129:	14.00m grading 13.09 g/t Au & 106 g/t Ag from 254.00m downhole
SNR26-132:	2.59m grading 13.81 g/t Au & 27 g/t Ag from 273.28m downhole

Table 1 shows assay results, including drill hole locations and orientations. Reported assay intervals represent downhole intersections, not true widths. True widths can be estimated at approximately 70-80% of the reported intervals.

Figure 1 shows the locations of the drill holes reported in this news release, as well as the other holes completed in 2026, the planned 2026 drill collar locations and the drill collars of pre-2026 drilling of the South Zone.

Figure 2 presents a South Zone cross-section highlighting drill hole SNR26-108, and Figure 3 presents a South Zone cross-section highlighting drill holes SNR26-116 and SNR26-129. The sections are viewed to the northwest (310°) and illustrate strong continuity of mineralization hosted within structurally controlled quartz veins and hydrothermal breccia zones.

Sampling, Laboratory Analyses and Quality Assurance/Quality Control (QA/QC)

Most core samples consist of halved drill core cut by manual sawing using industry standard core saws. In rare cases, and where required by physical core conditions, manual splitting may be used. Half of the core is retained in the original core box for reference samples and any required future work, including QA/QC. Core samples, controlled by a unique bar-coded reference number, are delivered to ALS’s Kamloops facility and prepared using the PREP-31 package. Each core sample is crushed to better than 70% passing a 2mm (Tyler 9 mesh, US Std. No.10) screen. A split of 250g is taken and pulverized to better than 85% passing a 75-micron (Tyler 200 mesh, US Std. No. 200) screen.

Further analytical and assay procedures are conducted in ALS’s North Vancouver facility. A 0.75g subsample of the pulverized split is subjected to four acid digestion and analyzed via ICP-MS (method code ME-MS61m (+Hg)) which reports a suite of 49 elements.

All samples are also analyzed for gold by fire assay with an AES finish, method code Au-ICP21 (30g sample size) or Au-ICP22 (50g sample size). Samples returning gold values over 10ppm are subjected to over-limit check assays using fire assay and a gravimetric finish (method code Au-GRA21 and a 30g sample size, or Au-GRAV22 and a 50g sample size). The switch to 50g aliquots applies to 2026 resource infill drill holes starting at, and including, SNR26-98. Other over-limit elements may also be subjected to ore grade analyses which vary depending on the element of interest.

ALS’s facilities are independent of the Corporation and Westhaven and are accredited to the ISO/IEC 17025 standard for gold assays, and all analytical methods include quality control materials at set frequencies with established data acceptance criteria.

QA/QC incorporates the laboratory’s internal quality assurance controls as well as Westhaven’s field controls, including the insertion of quarter core duplicates, certified reference materials and blanks, each at a rate of roughly one per 20-25 core samples. Additional blanks are inserted following samples with visible gold or significant concentrations of ginguro (fine grained bands of dark gray to black sulphides).

QA/QC data are evaluated on receipt for failures, and appropriate action is taken if results for duplicates, standards and blanks fall outside allowed tolerances. Westhaven’s ongoing QA/QC programs are consistent with industry best practices and include auditing of all exploration data. Any significant changes will be reported when available.

Figure 1 – Plan View Map September 2026

Figure 2 – South Zone Cross Section A-A’

Figure 3 – South Zone Cross Section B-B’

Table 1 – Assay Highlights

ABOUT DUNDEE CORPORATION:

Dundee Corporation is a public Canadian independent mining-focused holding company, listed on the Toronto Stock Exchange (“TSX”) under the symbol “DC.A”. The Corporation is engaged in the identification, evaluation, and advancement of mineral resource opportunities within the mining sector. The Corporation is actively pursuing interests in mining and exploration projects at various stages of development. In connection with these activities, the Corporation conducts technical, geological, and financial due diligence and may enter into joint arrangements, strategic partnerships, and other arrangements with third parties, with its level of involvement in project development and operations varying depending on the nature of the opportunity. The Corporation may support the advancement of mining opportunities through involvement in development planning and oversight of key technical workstreams.

Qualified Person

The scientific and technical information in this news release has been reviewed and approved by Robin Hopkins, P.Geo. (NT/NU), Vice President, Exploration for Westhaven and a Qualified Person for Westhaven under the definitions established by National Instrument 43-101 Standards of Disclosure for Mineral Projects. Mr. Hopkins is independent of Dundee.

FOR FURTHER INFORMATION PLEASE CONTACT:

Investor and Media Relations
T: (416) 864-3584
E: ir@dundeecorporation.com

FORWARD-LOOKING STATEMENTS:

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. These forward-looking statements are made as of the date of this news release and Dundee does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law.

Forward-looking statements in this news release may include, but are not limited to, statements with respect to completing approximately 50,000m of drilling during the year; completing an updated South Zone mineral resource estimate and the planned Pre-Feasibility Study and timing thereof; future planned activities; future mineral production and future growth potential for the Shovelnose project; the interpretation of preliminary results from exploration undertaken to date at the Shovelnose project using various exploration techniques and analysis; statements with respect to potential styles of epithermal mineralization at the Shovelnose project; and, the possibility that the Shovelnose project may host multiple gold bearing epithermal systems.

In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are based on the opinions and estimates of management of Dundee as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Assumptions have been made regarding, among other things, the price of gold and other precious metals; costs of exploration and development; the estimated costs of development of the Shovelnose project; Westhaven’s ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

Although management of Dundee have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Many factors, both known and unknown, could cause actual results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information. Such factors include, without limitation: precious metals price volatility; regulatory, consent or permitting delays; risks relating to reliance on Westhaven’s management team and outside contractors; risks regarding mineral resources and reserves; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; laws and regulations governing the environment, health and safety; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; Westhaven’s interactions with surrounding communities; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; and the factors identified in Dundee’s other public disclosure available on SEDAR+ at www.sedarplus.ca. Mineral exploration involves a high degree of risk and few properties, which are explored, are ultimately developed into producing mines. There can be no assurance that such forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.

A photo accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37b507f1-e083-4a89-a4cb-78481864ec6b

https://www.globenewswire.com/NewsRoom/AttachmentNg/1b57b993-a7d3-4f51-b489-49766b30db8d

https://www.globenewswire.com/NewsRoom/AttachmentNg/8838642d-f8d5-4385-8ccf-8b0375b90053

https://www.globenewswire.com/NewsRoom/AttachmentNg/2d113d87-0407-42fb-8b77-b2d9f50e9393

MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Jaime K. Pickett, DVM, MBA, to its Board of Directors, effective September 22, 2026.

“We are pleased to welcome Dr. Jaime Pickett to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Jaime brings a valuable combination of veterinary expertise, executive leadership and experience growing veterinary care organizations. Her understanding of clinical practice, hospital operations and animal-health technology will provide an important perspective as we work to expand product adoption, strengthen relationships with veterinarians and pursue opportunities for sustainable growth.”

Dr. Pickett is a veterinary healthcare executive, entrepreneur and board leader with more than 20 years of experience in animal health, multi-site operations, corporate strategy, business development and product commercialization. She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, providing clinical, regulatory, commercialization and strategic guidance for emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary Medical Officers and is a Scenthound multi-unit franchisee.

From 2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.

Dr. Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s University and a Bachelor of Arts from Johns Hopkins University. She also completed the Global C-Suite Program through Wharton Executive Education at the University of Pennsylvania. She is a member of the American Veterinary Medical Association and served for nine years on the University of Florida College of Veterinary Medicine Admissions Committee.

“I am excited to join PetVivo’s Board and contribute both a veterinarian’s perspective and my experience building and leading animal-health businesses,” said Dr. Pickett. “Bringing new technologies into veterinary practice requires an understanding of clinical needs, practice operations and the support veterinary teams need to evaluate and adopt them. I look forward to working with John and the team to help advance PetVivo’s commercial strategy, strengthen connections with the veterinary community and create long-term value for shareholders.”

Dr. Pickett fills the vacancy created by Diane Levitan’s resignation, effective September 22, 2026. The Board thanks Dr. Levitan for her leadership, guidance and contributions during her tenure. Following these changes, the Board continues to consist of six directors.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG^® with OsteoCushion^® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

MINNEAPOLIS, MN, US, Sept. 22, 2026 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026.

“We are pleased to welcome Michael Handley to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Michael brings extensive experience in building life sciences companies, raising capital and guiding technologies through development and commercialization. His perspective across biotechnology, pharmaceuticals and medical devices will be valuable as we work to expand adoption of our products, evaluate strategic opportunities and build long-term shareholder value.”

Mr. Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience spans corporate strategy and governance, capital markets, mergers and acquisitions, licensing, clinical development, regulatory affairs and global commercialization.

Mr. Handley most recently served as Chief Executive Officer and a director of Valion Bio, Inc. Previously, he was President, Chief Executive Officer and Chairman of Statera Biopharma, Inc., and held chief executive and director roles at Immune Therapeutics, Corp and Armis Biopharma. He also helped found Vessix Vascular, Inc., where he served as Vice President of Clinical, Quality and Regulatory until its acquisition by Boston Scientific Corporation in 2012.

Mr. Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania.

“I am excited to join PetVivo’s Board and work with John and the leadership team,” said Mr. Handley. “PetVivo’s focus on bringing innovative technologies to veterinary medicine, together with the potential to develop applications in human health, aligns closely with my experience in life sciences development and commercialization. I look forward to helping the Company evaluate growth opportunities, develop strategic relationships and advance its business in ways that support veterinarians, the animals they care for and, over time, potential human healthcare applications, while building long-term shareholder value.”

Mr. Handley fills the vacancy created by Joseph Jasper’s resignation, effective September 22, 2026. The Board thanks Mr. Jasper for his leadership, guidance and contributions during his tenure. Following these changes, the Board continues to consist of six directors.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG^® with OsteoCushion^® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.